<DOC>
	<DOCNO>NCT02597322</DOCNO>
	<brief_summary>Axitinib ( AXITINIB ) oral , potent , selective inhibitor vascular endothelial growth factor receptor 1 , 2 , 3 achieve objective response rate 44.2 % phase II study cytokine-refractory metastatic renal-cell cancer patient . Pre-surgical treatment Axitinib could allow substantial proportion patient large organ confine tumor benefit NSS . The Objective determine efficacy Axitinib administer prior surgery patient large organ confine tumor primarily suitable NSS ( cT2aNoNxM0 ) shift radical nephrectomy indication nephron spar procedure .</brief_summary>
	<brief_title>Study Axitinib Downstaging Large Renal Tumors Not Primarily Suitable Partial Nephrectomy ( AXIPAN )</brief_title>
	<detailed_description>Radical nephrectomy ( RN ) current standard care large organ confine renal tumor . Experience surgical technical improvement allow feasibility Nephron Sparing Surgery ( NSS ) tumor large 4 cm 7cm . Very limited data exist regard feasibility safety NSS tumor large 7cm . It demonstrate NSS compare RN offer similar oncological outcome well preserve renal function thus improve overall survival . The purpose study test possibility offering patient large organ confine renal tumor , candidate radical nephrectomy accord current guideline benefit partial nephrectomy thanks axitinib neo-adjuvant treatment .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Patients must sign IRB/ECapproved informed consent . Age ≥ 18 Histologically proven clear cell RCC ( obtain CT US guide biopsy ) cT2a N0NxM0 Renal tumor accord 2009 TNM classification ( tumor Ø &gt; 7cm ; ≤ 10 cm ) No evidence preexist uncontrolled hypertension document 2 baseline blood pressure read take least 1 hour apart . Normal renal function ( MDRD creatinin clearance ≥ 60 ml/min ) Patients must adequate organ function define : Platelets ≥ 150 x 109/L , hemoglobin &gt; 9 g/dl , absolute neutrophil count ( ANC ) &gt; 1.5 x 109/L ; Bilirubin &lt; 2 mg/dL , aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 2.5 time upper limit normal ; Total cholesterol ≤ 9.1 mmol/l triglyceride level ≤ 4.5 mmol/l Urinary protein &lt; 2+ urine dipstick . Patients reproductive potential must use medically acceptable contraceptive method . Beneficiary social coverage ( except AME ) Patients &lt; 50 % clear cell histology Evidence locally advance disease : cT stage≥T2b , N Stage≥1 metastatic disease ( M1 ) Patients must pregnant lactating . Patients must uncompensated coronary artery disease history myocardial infarction severe unstable angina within past six month severe diabetes mellitus severe arterial peripheral disease deep venous arterial thrombosis embolism past 3 month . Patients must need curative anticoagulant . Patients must medical/systemic psychiatric disorder incompatible study . Patients must history significant gastric small bowel resection , malabsorption syndrome , lack integrity upper gastrointestinal tract may compromise absorption Axitinib unavailability oral route .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Axitinib</keyword>
	<keyword>T2a Renal tumor</keyword>
	<keyword>organ confine tumor</keyword>
	<keyword>nephron spar surgery</keyword>
	<keyword>nephron spar procedure</keyword>
	<keyword>radical nephrectomy</keyword>
</DOC>